
Women being treated for osteoporosis expressed an overwhelming preference for monthly dosing over weekly dosing in a recent nationwide survey. The study, directed by Wulf Utian of The Cleveland Clinic in Cleveland, OH, supports the monthly dosing schedule offered by ibandronate, a competing oral bisphosphonate.